Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Why Relay Therapeutics Stock Popped on Wednesday
Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise
Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Relay's treatment shown to shrink vascular malformations in mid-stage trial
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy Transcript
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
JPMorgan Chase & Co. Reduces Position in Relay Therapeutics, Inc. $RLAY
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
SG Americas Securities LLC Acquires 189,004 Shares of Relay Therapeutics, Inc. $RLAY
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week High on Analyst Upgrade
Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?
Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst
Relay Therapeutics (NASDAQ:RLAY) Hits New 12-Month High After Better-Than-Expected Earnings
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run
$207B Market Shift: The Race for Fast Track Approval in Oncology
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism
Relay Therapeutics Reports 'Robust Activity' For Precision Breast Cancer Drug
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares
Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet
Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Relay Therapeutics Is A Buy For Its Superb Safety Data
Wall Street Analysts Believe Relay Therapeutics (RLAY) Could Rally 116.91%: Here's is How to Trade